Press releases
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Oct 7, 2016
Boston Scientific Corporation (NYSE: BSX) today announced that its wholly owned merger subsidiary, Falcon Merger Corp., has launched its previously announced tender offer for all shares of...
-
Oct 3, 2016
Boston Scientific Corporation (NYSE: BSX) will webcast its conference call discussing financial results and business highlights for the third quarter ended September 30, 2016 on Wednesday, October...
-
Sep 27, 2016Acquisition Will Expand Endoscopy Gastroenterology Portfolio
Boston Scientific (NYSE: BSX) and EndoChoice Holdings, Inc. (NYSE: GI) today announced the companies have entered into a definitive agreement under which Boston Scientific has agreed to acquire...
-
Sep 19, 2016
Boston Scientific Corporation (NYSE: BSX) has received CE Mark for the LOTUS Edge™ Valve System, the company's next generation transcatheter aortic valve implantation (TAVI) technology. The...
-
Aug 30, 2016
Boston Scientific Corporation (NYSE: BSX) will participate in the Morgan Stanley Global Healthcare Conference on September 13, in New York City. Mike Mahoney, chief executive officer, and Dan...
-
Aug 24, 2016
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the Wells Fargo Healthcare Conference on September 7, in Boston. Mike Mahoney, chief executive officer, Dan Brennan,...
-
Aug 9, 2016Approval Grants MR-Conditional Labeling to All EMBLEM S-ICD Systems, Expands ImageReady™ Portfolio
Boston Scientific (NYSE: BSX) has received U.S. Food and Drug Administration (FDA) approval for the EMBLEM™ MRI Subcutaneous Implantable Defibrillator (S-ICD) System, as well as magnetic...
-
Aug 1, 2016
Boston Scientific Corporation (NYSE: BSX) is scheduled to participate in the 36th Annual Canaccord Genuity Growth Conference on August 11 in Boston and the 2016 Wedbush PacGrow Healthcare...
-
Jul 28, 2016
Boston Scientific Corporation (NYSE: BSX) generated sales of $2.126 billion during the second quarter ended June 30, 2016, compared to the company's guidance range for the quarter of $2.010 to...
-
Jul 27, 2016Addition of Leading Radiofrequency Ablation Company Expands Therapeutic Options for Patients with Chronic Pain
Addition of leading radiofrequency ablation company expands therapeutic options for patients with chronic pain
